Randomized controlled trial to investigate the retention time of intravesical instillation therapy with pirarubicin for non-muscule invasive bladder cancer following transurethral resection of bladder tumor.

Randomized controlled trial to investigate the retention time of intravesical instillation therapy with pirarubicin for non-muscule invasive bladder cancer following transurethral resection of bladder tumor. - Investigation of retention time of intravesical instillation therapy with pirarubicin for non-muscule invasive bladder cancer.Investigation of retention time of intravesical instillation therapy with pirarubicin for non-muscule invasive bladder cancer.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006861

Enrollment

160

Registered

2011-12-09

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intermediate risk non-muscle invasive bladder cancer

Interventions

Intravesical instillation therapy with pirarubicin 30mg a total of 9 times,with the first instillation at the time of transurethral resection of bladder tumor and then 8 times. A group with a retenti

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Intermediate risk non-muscule invasive bladder cancer. 2. PS 0-2 3. Patients who can periodically undergo cystoscopic surveillance of recurrence after surgery. 4. All tumors were resected patients with transurethral resection of bladder. 5. Informed consent on document for this study should be obtained form the patient.

Exclusion criteria

Exclusion criteria: 1. Patients who previously underwent intravesical therapy with BCG. 2. The patients underwent maintenance intravesical therapy of an anticancer agent. 3. Patients with active other malignant disease. 4. Patients with historically or presently disease of upper urinary tract urothelial cell carcinoma. 5. Funcion of all organs are without severe dysfunction. 6. Inappropriate patients for this study judged by the physicians.

Design outcomes

Primary

Measure	Time frame
Quality of life	—

Secondary

Measure	Time frame
Safety Recurrence-free rate	—

Countries

Japan

Contacts

Public ContactYoshihiro Wada

Kumamoto Univerisity Faculty of Life Sciences, Department of Urology

yoshiwad@kumamoto-u.ac.jp096-373-5240

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026